Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity

INTRODUCTION: There is no study specifically focused on SARS-CoV-2 vaccine in primary Sjögren’s syndrome (pSS). OBJECTIVES: To assess the immunogenicity, safety, possible effects on disease activity, and autoantibody profile of the Sinovac-CoronaVac vaccine in pSS. METHODS: Fifty-one pSS patients an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasoto, Sandra Gofinet, Halpern, Ari Stiel Radu, Guedes, Lissiane Karine Noronha, Ribeiro, Ana Cristina Medeiros, Yuki, Emily Neves Figueiredo, Saad, Carla Gonçalves Schahin, da Silva, Clovis Artur Almeida, de Vinci Kanda Kupa, Léonard, Villamarín, Lorena Elizabeth Betancourt, de Oliveira Martins, Victor Adriano, Martins, Carolina Campagnoli Machado Freire, Deveza, Giordano Bruno Henriques, Leon, Elaine Pires, Bueno, Cleonice, Pedrosa, Tatiana Nascimento, Santos, Roseli Eliana Beseggio, Soares, Renata, Aikawa, Nádia Emi, Bonfa, Eloisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934123/
https://www.ncbi.nlm.nih.gov/pubmed/35306594
http://dx.doi.org/10.1007/s10067-022-06134-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934123/
https://www.ncbi.nlm.nih.gov/pubmed/35306594
http://dx.doi.org/10.1007/s10067-022-06134-x

Ejemplares similares